Competition to be intensified in hepatitis B drug market

Published: 2012-09-20 07:00:00

Updated: 2012-09-20 07:00:00

Competition in the domestic hepatitis B drug market is likely to heat up because Yuhan Corp., Korea’s exclusive seller of Gilead Science Viread, are poised to occupy the runner-up slot by deploying aggressive marketing strategies of Viread, which has been recently included in the insurance list.

Since its launch in August 2006, Bristol-Myers Squibb’s Baraclude’ garnered 120.9 billion won in ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.